Analysts rate Spero Therapeutics Inc. (SPRO:NSD) with a Strong Buy rating and a $17 target

STA Research
by: STA Research
Spero Therapeutics Inc

Based on the Spero Therapeutics stock forecast from 4 analysts, the average analyst SPRO stock price target is USD 17.33 over the next 12 months. Spero Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of SPRO stock forecast is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, Spero Therapeutics stock price was USD 1.13Spero Therapeutics stock price has changed by +0.25% over the past week, +0.33% over the past month and -93.77% over the last year.

About Spero Therapeutics Inc. (SPRO:NSD):

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.


What we like:

Underpriced compared to book value:

SPRO stock price is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow:

Spero Therapeutics stock had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth:

Spero stock has shown top quartile revenue growth in the previous 5 years compared to its sector.


What we don’t like:

Low market capitalization:

Spero stock is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow:

Spero Therapeutics stock had negative total cash flow in the most recent four quarters.

Low Earnings Growth:

Spero stock has shown below median earnings growth in the previous 5 years compared to its sector


Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.